Cintia Piccina Sells 6,713 Shares of Autolus Therapeutics (NASDAQ:AUTL) Stock

Key Points

• Insider sale: Cintia Piccina sold 6,713 Autolus Therapeutics shares at an average price of $2.34, receiving $15,708.42. The transaction reduced her stake by 33.57% to 13,287 shares.
• Recent performance and earnings: AUTL traded at $2.29, near its one-year high of $2.58, after reporting quarterly revenue of $45.69 million and an adjusted loss of $0.15 per share, both better than analysts expected.
• Investor outlook: Institutional investors own 72.83% of the company, while analysts maintain a “Moderate Buy” consensus and an average price target of $10.00, substantially above the current share price.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) insider Cintia Piccina sold 6,713 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $2.34, for a total value of $15,708.42. Following the completion of the sale, the insider owned 13,287 shares of the company's stock, valued at approximately $31,091.58. This trade represents a 33.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Autolus Therapeutics Price Performance

AUTL stock traded up $0.05 during trading hours on Thursday, hitting $2.29. 1,772,956 shares of the stock traded hands, compared to its average volume of 1,811,079. The stock has a 50-day simple moving average of $1.86 and a 200 day simple moving average of $1.66. Autolus Therapeutics PLC Sponsored ADR has a one year low of $1.17 and a one year high of $2.58. The company has a market cap of $609.51 million, a P/E ratio of -2.16 and a beta of 2.10. The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%.The firm had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. Equities analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.75 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

A number of hedge funds have recently modified their holdings of the business. Mak Capital One LLC grew its holdings in shares of Autolus Therapeutics by 15.3% during the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company's stock valued at $59,711,000 after buying an additional 3,987,727 shares in the last quarter. Armistice Capital LLC raised its position in Autolus Therapeutics by 12.2% during the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company's stock valued at $34,825,000 after buying an additional 1,900,000 shares during the period. Syncona Portfolio Ltd purchased a new stake in Autolus Therapeutics in the 2nd quarter worth about $26,625,152. Schroder Investment Management Group lifted its stake in Autolus Therapeutics by 12.5% in the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company's stock worth $18,694,000 after acquiring an additional 1,056,092 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Autolus Therapeutics by 108.1% during the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company's stock worth $3,308,000 after acquiring an additional 1,054,458 shares during the period. Hedge funds and other institutional investors own 72.83% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on AUTL shares. Wall Street Zen upgraded shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, August 16th. Weiss Ratings upgraded shares of Autolus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 13th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $10.00.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source